Skip to content
An Initiative of AVAC
Search
Back to Resource Library

GBGMC Country Profiles

5 February 2026

These country profiles provide concise, actionable snapshots of the HIV prevention and treatment landscape for key populations across multiple countries, including: Brazil, Eswatini, France, Kenya, Malawi, Mozambique, Nigeria, the Philippines, South Africa, Uganda, Ukraine, the United States, Vietnam, Zambia, and Zimbabwe.

Country profiles highlight:

  • History of PrEP introduction
  • Updates on PrEP Products
  • Key population epidemiology and estimates
  • PrEP and long-acting prevention readiness
  • Policy and regulatory environments
  • Long-acting PrEP need by countries
  • Service delivery opportunities and barriers
  • Community-identified priorities for scale-up

Topic(s): Community/Advocacy, Demand Creation/Marketing, Monitoring & Evaluation, Normative Guidance/Policies, Service Delivery

Product(s): Cabotegravir, Dapivirine Vaginal Ring, Injectable Prep, Lenacapavir, Oral PrEP, TDF/xTC

Population(s): Cisgender Men, Gay and Bisexual Men Who Have Sex With Men, Nonbinary People, People Who Use Drugs, Sex Workers, Trans Men, Trans Women, Young Men Who Have Sex with Men

Region(s): East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, North America, Sub-Saharan Africa

Format(s): Factsheet

Countries: Brazil, Eswatini, France, Kenya, Lesotho, Malawi, Mozambique, Nigeria, Philippines, South Africa, Uganda, Ukraine, United States, Vietnam, Zambia, Zimbabwe

Source(s): GBGMC

Type: External Link

Visit

Featured Resources

External Link

Integrated Study Dashboard

This dashboard, produced under the BioPIC project, reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late stage biomedical HIV PrEP options, including lenacapavir for PrEP, cabotegravir, and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have questions on…
External Link

Country Planning for Product Introduction Matrix

AVAC’s Country Planning for Product Introduction Matrix tracks key indicators for the introduction of new PrEP products, including lenacapavir (LEN), cabotegravir (CAB), and the Dapivirine Vaginal Ring (DVR), by country, including regulatory status, late stage clinical trials and implementation research, procurement plans, and recent oral PrEP provision.
Document

South Africa Lenacapavir Implementation Guidelines, 2025

This guideline, developed by South Africa’s National Department of Health, is intended to provide comprehensive clinical, programmatic, and operational direction for the safe, effective, and equitable rollout of lenacapavir as a long-acting injectable option for HIV PrEP in South Africa.
Document

Ukraine HIV Clinical Guidelines 2025

These clinical guidelines, released by the Ukraine Ministry of Health in 2025, include the latest recommendations for HIV services, including oral PrEP and injectable cabotegravir (CAB) for PrEP.
External Link

BLUPrInt PrEP Program Builder

The BLUPrInt PrEP Program Builder breaks down the process of making PrEP – whether oral or injectable – available in your setting into six manageable and coherent program components. Each program component includes a Step-by-Step Guide that presents key decision points and health equity considerations that are crucial to PrEP program development, a templated Standard…
Spreadsheet

Site/Facility Readiness Assessment Tool to Support Lenacapavir for HIV Prevention Introduction

This tool, developed by Wits RHI and CHAI with support from Unitaid, is intended to provide insight into the current state of PrEP services and to identify critical barriers and facilitators to PrEP implementation with a focus on preparing for Lenacapavir (LEN) introduction according to national requirements. Findings from readiness assessment visits using this tool…
Document

Getting LEN Rollout Right: Resources and Tools

The resources listed in this document, alongside insights drawn from the report Getting PrEP Rollout Right This Time, can support countries in the early stages of LEN planning. These tools are being disseminated as part of a coordinated effort between AVAC, CHAI, CIFF, the Global Fund, PEPFAR, PSI, Unitaid, Wits RHI, and WHO under the…
Document

Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda, 2022

These guidelines, produced in 2022 by the Uganda Ministry of Health, provide guidance on the diagnosis of HIV, the care of people living with HIV, and the use of antiretroviral drugs for treating and preventing HIV infection, including injectable cabotegravir and the dapivirine vaginal ring.
Document

Malawi Service Delivery Guidelines and Standard Operating Procedures for the Provision of HIV Pre-Exposure Prophylaxis using Oral or Long-acting Injectable Options (2024)

The document, produced by the Malawi Ministry of Health, is a guideline to support funders, implementing partners, district health team leads and service providers in implementing Oral and Long-Acting Injectable PrEP in Malawi.
External Link

Preferences for Long-acting Injectable HIV Pre-exposure Prophylaxis Service Delivery among Male and Female Sex Workers in Uganda: A discrete choice experiment

This article from PLOS Global Public Health explores service delivery preferences for injectable cabotegravir among heterosexual male sex workers and female sex workers in Uganda.